SOURCE: IO Circuit

September 19, 2006 07:00 ET

(OTC BB: BMSN) Appoints Daniel Gomez as Director of Engineering

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by the IO Circuit

LAKE HARMONY, PA -- (MARKET WIRE) -- September 19, 2006 -- Bio-Matrix Scientific Group Inc. (OTCBB: BMSN), a biotechnology company focused on stem cell cryogenics and disposable stem cell / tissue transfer instruments, announced today the appointment of Daniel Gomez as Director of Engineering. Mr. Gomez will be responsible for the design and engineering of medical devices and the implementation of new technologies.

Mr. Gomez is an industry veteran and brings over thirty-five years of experience in all facets of manufacturing; most recently serving as President of Collective Technologies, Inc. where he was responsible for leadership, while overseeing the overall strategy of the company.

Brian Pockett, Managing Director and COO stated, "Dan brings strong technical expertise, in-depth knowledge of the manufacturing industry and a proven ability to lead innovative solutions to meet our client's needs going forward."

To read the complete release, go to http://www.cyberelease.com/bmsn91906.htm

Other active stocks are Sun Healthcare Group, Inc. (NASDAQ: SUNH), 21st Century Holding Company (NASDAQ: TCHC) and Applied Micro Circuits Corporation (NASDAQ: AMCC).

Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for informational purposes only and is neither a solicitation to buy nor an offer to sell securities. A Third Party has hired and paid $995.00 for the publication and circulation of this report. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation and do no trading of any kind.

Contact Information